Subscribe
shutterstock_733304062_casimiro_pt
Casimiro PT / Shutterstock.com
26 July 2019AmericasSarah Morgan

Bio-Rad wins injunction against 10X Genomics

Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?